EC
LXRX icon

EntryPoint Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

EntryPoint Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.7K Buy
48,498
+14,880
+44% +$21.6K 0.02% 715
2025
Q4 		$38.7K Buy
+33,618
New +$46.2K 0.02% 633
2024
Q1 		– Sell
-323,968
Closed -$496K – 1615
2023
Q4 		$496K Buy
+323,968
New +$385K 0.48% 6

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

EntryPoint Capital's LXRX Position: Q1 2026 in Review

EntryPoint Capital increased its Lexicon Pharmaceuticals (LXRX) stake by 44% in Q1 2026, buying an estimated $21.6K and bringing the position to 48,498 shares worth $75.7K. The position accounts for 0.02% of the portfolio, ranked #715.

EntryPoint Capital first reported a position in LXRX in Q4 2023 and has held it in 3 quarters since. The position peaked at $496K in Q4 2023. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • EntryPoint Capital held 48,498 shares of Lexicon Pharmaceuticals worth $75.7K as of Q1 2026.
  • EntryPoint Capital bought 14,880 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $21.6K.
  • Lexicon Pharmaceuticals made up 0.02% of EntryPoint Capital's portfolio in Q1 2026, its #715 holding.
  • EntryPoint Capital first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • EntryPoint Capital's Lexicon Pharmaceuticals position peaked at $496K in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.